But it is more survivable now than it used to be. That is due in part to advances in the approach to treating the cancer, Dr. Truty says.
Patients that can have surgery for their pancreatic cancer live longer than those who cannot. Unfortunately, in the past, surgery wasn’t an option for most patients, but with better chemotherapy came dramatic changes. Now, more patients are considered candidates for curative surgery.
“Those patients that are able to undergo chemotherapy prior to the surgery tend to do much better than they historically have done,” Dr. Truty says.
That includes patients who may have been considered inoperable elsewhere due to complex tumors involving blood vessels. Mayo Clinic is the first and only center that routinely uses positron emission tomography, or PET, scans to help determine if that chemotherapy is effective.
“This is what we want to see at the beginning; we want to see a tumor lighting up really bright prior to chemotherapy. And then, after chemotherapy, we want to see it sort of disappear — the activity that would suggest that chemotherapy was effective. And then when we ultimately operate on these patients and we take the tumors out, the pathologist tells us that all the cancer is dead,” Dr. Truty explains.
The primary goal for any patient with pancreatic cancer is to extend their life and maintain or improve their quality of life. Advances like this are offering patients hope.
“Without question, they should have hope,” Dr. Truty says.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.